BioPorto (CPSE:BIOPOR) - Aandelenkoers, Nieuws & Analyse

BIOPOR Overzicht aandelen

BioPorto A/S, een bedrijf voor in-vitro diagnostiek, levert biomarker tools en antilichamen voor klinisch onderzoek in Europa, Noord-Amerika, Azië en internationaal. Meer informatie

BIOPOR fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 29.18% per jaar groeien

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 35% per jaar dalen.

Heeft geen zinvolle omzet ( DKK34M )

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aandeelhouders zijn het afgelopen jaar verwaterd

+ 2 meer risico's

BioPorto A/S Concurrenten

Bavarian Nordic

CPSE:BAVA

DKK 14.6b

Genmab

CPSE:GMAB

DKK 93.0b

TCM Biotech International

TPEX:4169

NT$3.5b

Protalix BioTherapeutics

NYSEAM:PLX

US$103.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor BioPorto
Historische aandelenkoersen
Huidige aandelenkoers	DKK 1.62
52 Week Hoogtepunt	DKK 3.85
52 Week Laag	DKK 1.21
Bèta	1.15
11 maand verandering	-13.26%
3 maanden verandering	-24.21%
1 Jaar Verandering	-33.80%
33 jaar verandering	-49.23%
5 jaar verandering	-48.26%
Verandering sinds IPO	-99.29%

Recent nieuws en updates

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

Oct 22

Recent updates

Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation

Oct 16

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

May 28

BioPorto A/S' (CPH:BIOPOR) Path To Profitability

Mar 01

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

Jan 24

A Look At BioPorto's (CPH:BIOPOR) CEO Remuneration

Dec 20

The BioPorto A/S (CPH:BIOPOR) Analysts Have Been Trimming Their Sales Forecasts

Nov 23

BioPorto A/S (CPH:BIOPOR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Nov 21

Rendement voor aandeelhouders

	BIOPOR	DK Biotechs	DK Markt
7D	-7.4%	-14.0%	-6.0%
1Y	-33.8%	-11.5%	4.2%

Rendement versus industrie: BIOPOR presteerde slechter dan de Danish Biotechs -sector, die het afgelopen jaar een rendement van -11.5 % opleverde.

Rendement versus markt: BIOPOR presteerde slechter dan Danish Market, dat het afgelopen jaar een rendement van 4.2 % opleverde.

Prijsvolatiliteit

Is BIOPOR's price volatile compared to industry and market?
BIOPOR volatility
BIOPOR Average Weekly Movement	6.2%
Biotechs Industry Average Movement	7.9%
Market Average Movement	4.2%
10% most volatile stocks in DK Market	10.4%
10% least volatile stocks in DK Market	2.5%

Stabiele aandelenkoers: De aandelenkoers van BIOPOR is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van BIOPOR is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Danish.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1917	27	Peter Eriksen	bioporto.com

BioPorto A/S, een bedrijf voor in-vitro diagnostiek, levert biomarkerinstrumenten en antilichamen voor klinisch onderzoek in Europa, Noord-Amerika, Azië en internationaal. Het bedrijf biedt de neutrofiele gelatinase-geassocieerde lipocalinetest aan, een kwantitatieve turbidimetrische immunoassay met deeltjesversterking, ontworpen voor gebruik op geautomatiseerde klinisch-chemische analysers; monoklonale antilichamen voor wetenschappelijk, farmaceutisch en klinisch onderzoek; enzyme-linked immunosorbent assay kits, evenals generieke snelle assay apparaten voor aangepaste laterale flow assays. BioPorto A/S werd opgericht in 1917 en is gevestigd in Hellerup, Denemarken.

BioPorto A/S Samenvatting

Hoe verhouden de winst en inkomsten van BioPorto zich tot de beurswaarde?
BIOPOR fundamentele statistieken
Marktkapitalisatie	DKK 696.90m
Inkomsten(TTM)	-DKK 50.01m
Inkomsten(TTM)	DKK 33.83m

20.6x

P/S-verhouding

-13.9x

Koers/Winstverhouding

Is BIOPOR overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BIOPOR resultatenrekening (TTM)
Inkomsten	DKK 33.83m
Kosten van inkomsten	DKK 9.55m
Brutowinst	DKK 24.28m
Overige uitgaven	DKK 74.29m
Inkomsten	-DKK 50.01m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.12
Brutomarge	71.76%
Nettowinstmarge	-147.84%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde BIOPOR op de lange termijn?

Bekijk historische prestaties en vergelijking

BIOPOR Overzicht aandelen

Beloningen

Risicoanalyse

BioPorto A/S Concurrenten

CPSE:BAVA

DKK 14.6b

CPSE:GMAB

DKK 93.0b

TPEX:4169

NT$3.5b

NYSEAM:PLX

US$103.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

New minor risk - Market cap size

Bioporto A/S Maintains Revenue Guidance for the Year 2024

BioPorto A/S Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL) for Adult Use at Massachusetts General Hospital

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

Consensus EPS estimates fall by 80%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

New minor risk - Market cap size

Bioporto A/S Maintains Revenue Guidance for the Year 2024

BioPorto A/S Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL) for Adult Use at Massachusetts General Hospital

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

Consensus EPS estimates fall by 80%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bioporto A/S Affirms Earnings Guidance for 2024

New major risk - Share price stability

New minor risk - Shareholder dilution

BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024

Bioporto A/S Provides Revenue Guidance for 2024

First quarter 2024 earnings released: kr.0.04 loss per share (vs kr.0.048 loss in 1Q 2023)

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

BioPorto A/S Announces CEO Changes

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

BioPorto A/S to Report Nine Months, 2024 Results on Oct 30, 2024

BioPorto A/S, Annual General Meeting, Apr 30, 2024

New major risk - Share price stability

BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United States

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Consensus estimates of losses per share improve by 16%

New major risk - Financial position

Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023

Bioporto A/S Announces Resignation of Neil Goldman as CFO

BioPorto A/S announced that it has received $0.11 million in funding

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

BioPorto A/S Maintains Earnings Guidance for the Year 2023

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

New minor risk - Shareholder dilution

High number of new and inexperienced directors

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

BioPorto A/S Maintains Financial Guidance for 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

BioPorto A/S, Annual General Meeting, Apr 27, 2023

BioPorto A/S Appoints Nis Kruse as EVP of Strategic Partnerships and Gm of EMEA & Apac

Less than half of directors are independent

BioPorto A/S Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

BioPorto A/S Revises Earnings Guidance for the Year 2022

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

BioPorto A/S Revises Earnings Guidance for the Year 2022

Second quarter 2022 earnings: Revenues exceed analyst expectations

BioPorto A/S Revises Earnings Guidance for the Year 2022

BioPorto A/S Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S

BioPorto A/S Appoints Dr. Prasad Devarajan as New Senior Medical Director

We're Keeping An Eye On BioPorto's (CPH:BIOPOR) Cash Burn Rate

BioPorto A/S Maintains its Earnings Guidance for the Year 2022

Price target decreased to kr.3.50

Less than half of directors are independent

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

BioPorto A/S Provides Earnings Guidance for the Full Year 2022

Is BioPorto (CPH:BIOPOR) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

Third quarter 2021 earnings released: kr.0.04 loss per share (vs kr.0.087 loss in 3Q 2020)

Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation

Second quarter 2021 earnings released: kr.0.051 loss per share (vs kr.0.077 loss in 2Q 2020)